Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer

This randomized controlled phase III trial aims to evaluate the use of electroacupuncture in combination with olanzapine-containing standard quadruple antiemetic drugs for the treatment of nausea and vomiting induced by highly emetogenic chemotherapy (HEC) in patients with breast cancer. Furthermore, it will analyze the relationship between single nucleotide polymorphism and electroacupuncture treatment for chemotherapy-induced nausea and vomiting.

Trial Details

NCT ID
NCT06200168
Phase
PHASE3
Sponsor
Jiuda Zhao
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Electroacupuncture
  • Standard antiemetic treatment
  • Sham electroacupuncture
Locations (sample)
  • Xining, Qinghai, China|36.62554,101.75739

Key Eligibility Criteria

  • Aged 18 years or older and aged 75 years or younger, of any nationality;
  • Eastern Cooperative Oncology Group performance status of 0-2;
  • Patients with breast cancer, with no restrictions on molecular typing; early-stage patients must not have undergone prior chemotherapy, while advan…
  • Predicted life expectancy of ≥3 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →